Neogenix Oncology, a biotechnology company which develops therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate and other cancers, has partnered with Cambridge Biomedical to develop pancreatic and colorectal cancer diagnostic serum ELISA assays.
Cambridge Biomedical provides expertise in assay optimization and validation within an FDA recognized laboratory that is CLIA certified and CAP accredited.
Neogenix has developed tumor specific biomarkers for the detection of pancreatic and colorectal cancer in tissue and serum.
The ELISA assay utilizes the Neogenix patent protected therapeutic monoclonal antibodies (NEO-101, NEO 201, NEO 301).
These diagnostic assays will serve as the companion products for the Neogenix anti-cancer mAb therapeutic pipeline and hold additional hope for early detection of pancreatic and colorectal cancer.
Cambridge Biomedical COO John Reddington said it is able to apply its analytical and regulatory expertise to accelerate the process to make these much needed products available to afflicted patients.